We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Health nut

31 August 2020 By Dasha Afanasieva

The $348 bln Swiss giant is buying allergy treatment firm Aimmune. It makes the first approved product for food allergies to the nut. The ingredient isn’t prominent in its portfolio, so CEO Mark Schneider will essentially get a lift from making rivals’ products more accessible.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.